BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:BLC - FR0000035370 - Common Stock
24.55 EUR
+0.05 (+0.2%)
BLC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 33 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of BLC while its profitability can be described as average. BLC is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
BLC had positive earnings in the past year.
In the past year BLC had a positive cash flow from operations.
BLC had positive earnings in 4 of the past 5 years.
In the past 5 years BLC always reported a positive cash flow from operatings.
1.2 Ratios
BLC has a worse Return On Assets (0.08%) than 74.19% of its industry peers.
With a Return On Equity value of 0.74%, BLC is not doing good in the industry: 67.74% of the companies in the same industry are doing better.
BLC's Return On Invested Capital of 6.37% is fine compared to the rest of the industry. BLC outperforms 64.52% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BLC is in line with the industry average of 6.56%.
The 3 year average ROIC (6.13%) for BLC is below the current ROIC(6.37%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.74% | ||
| ROIC | 6.37% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.22%
ROIC(3y)6.13%
ROIC(5y)5.72%
1.3 Margins
BLC has a worse Profit Margin (0.11%) than 74.19% of its industry peers.
In the last couple of years the Profit Margin of BLC has declined.
With a decent Operating Margin value of 8.14%, BLC is doing good in the industry, outperforming 64.52% of the companies in the same industry.
In the last couple of years the Operating Margin of BLC has remained more or less at the same level.
BLC has a better Gross Margin (67.80%) than 74.19% of its industry peers.
In the last couple of years the Gross Margin of BLC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.14% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% |
OM growth 3Y5.34%
OM growth 5Y0.66%
PM growth 3Y-66.7%
PM growth 5Y-48.68%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BLC is creating some value.
BLC has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, BLC has about the same amount of shares outstanding.
BLC has a better debt/assets ratio than last year.
2.2 Solvency
BLC has an Altman-Z score of 1.39. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.39, BLC is not doing good in the industry: 67.74% of the companies in the same industry are doing better.
The Debt to FCF ratio of BLC is 12.84, which is on the high side as it means it would take BLC, 12.84 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 12.84, BLC is doing worse than 61.29% of the companies in the same industry.
A Debt/Equity ratio of 5.31 is on the high side and indicates that BLC has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 5.31, BLC is doing worse than 90.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.31 | ||
| Debt/FCF | 12.84 | ||
| Altman-Z | 1.39 |
ROIC/WACC1.27
WACC5.02%
2.3 Liquidity
BLC has a Current Ratio of 1.39. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.39, BLC is doing good in the industry, outperforming 74.19% of the companies in the same industry.
BLC has a Quick Ratio of 1.19. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
BLC has a better Quick ratio (1.19) than 77.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 158.33% over the past year.
BLC shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -46.37% yearly.
BLC shows a small growth in Revenue. In the last year, the Revenue has grown by 6.35%.
BLC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.12% yearly.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
The Earnings Per Share is expected to grow by 6.18% on average over the next years.
Based on estimates for the next years, BLC will show a small growth in Revenue. The Revenue will grow by 7.69% on average per year.
EPS Next Y18.99%
EPS Next 2Y0.72%
EPS Next 3Y6.18%
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 350.71, which means the current valuation is very expensive for BLC.
BLC's Price/Earnings ratio is a bit more expensive when compared to the industry. BLC is more expensive than 77.42% of the companies in the same industry.
BLC is valuated expensively when we compare the Price/Earnings ratio to 26.39, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 9.82 indicates a reasonable valuation of BLC.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BLC indicates a rather cheap valuation: BLC is cheaper than 87.10% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.84, BLC is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 350.71 | ||
| Fwd PE | 9.82 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BLC indicates a rather cheap valuation: BLC is cheaper than 87.10% of the companies listed in the same industry.
80.65% of the companies in the same industry are more expensive than BLC, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.65 | ||
| EV/EBITDA | 5.62 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)18.47
PEG (5Y)N/A
EPS Next 2Y0.72%
EPS Next 3Y6.18%
5. Dividend
5.1 Amount
No dividends for BLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:BLC (12/19/2025, 7:00:00 PM)
24.55
+0.05 (+0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.78%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap180.93M
Revenue(TTM)491.18M
Net Income(TTM)530.00K
Analysts83.33
Price Target36.72 (49.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP107.55%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-8.5%
EPS NY rev (3m)-16.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 350.71 | ||
| Fwd PE | 9.82 | ||
| P/S | 0.37 | ||
| P/FCF | 5.65 | ||
| P/OCF | 1.97 | ||
| P/B | 2.51 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.62 |
EPS(TTM)0.07
EY0.29%
EPS(NY)2.5
Fwd EY10.18%
FCF(TTM)4.34
FCFY17.69%
OCF(TTM)12.48
OCFY50.85%
SpS66.65
BVpS9.77
TBVpS-16.27
PEG (NY)18.47
PEG (5Y)N/A
Graham Number3.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.74% | ||
| ROCE | 8.67% | ||
| ROIC | 6.37% | ||
| ROICexc | 6.75% | ||
| ROICexgc | 12.06% | ||
| OM | 8.14% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% | ||
| FCFM | 6.51% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.22%
ROIC(3y)6.13%
ROIC(5y)5.72%
ROICexc(3y)6.56%
ROICexc(5y)6.11%
ROICexgc(3y)13.97%
ROICexgc(5y)12.75%
ROCE(3y)8.35%
ROCE(5y)7.8%
ROICexgc growth 3Y2.87%
ROICexgc growth 5Y-0.99%
ROICexc growth 3Y7.59%
ROICexc growth 5Y0.26%
OM growth 3Y5.34%
OM growth 5Y0.66%
PM growth 3Y-66.7%
PM growth 5Y-48.68%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score7
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.31 | ||
| Debt/FCF | 12.84 | ||
| Debt/EBITDA | 3.78 | ||
| Cap/Depr | 98.36% | ||
| Cap/Sales | 12.22% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.12% | ||
| Profit Quality | 6037.74% | ||
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 1.39 |
F-Score7
WACC5.02%
ROIC/WACC1.27
Cap/Depr(3y)93.08%
Cap/Depr(5y)92.09%
Cap/Sales(3y)11.16%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y18.99%
EPS Next 2Y0.72%
EPS Next 3Y6.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
EBIT growth 1Y17.78%
EBIT growth 3Y7.03%
EBIT growth 5Y5.81%
EBIT Next Year137.78%
EBIT Next 3Y39.06%
EBIT Next 5YN/A
FCF growth 1Y1.88%
FCF growth 3Y107.42%
FCF growth 5Y33.53%
OCF growth 1Y13.78%
OCF growth 3Y17.4%
OCF growth 5Y14.22%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
What is the valuation status for BLC stock?
ChartMill assigns a valuation rating of 5 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.
What is the valuation of BASTIDE LE CONFORT MEDICAL based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 350.71 and the Price/Book (PB) ratio is 2.51.
How sustainable is the dividend of BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 107.55%.